PPT-Antiplatelet

Therapy for the Secondary Prevention of Cerebrovascular Disease Working Group Ashfaq Shuaib MD FRCP Philip Teal MD FRCP Canadian Cardiovascular Society Antiplatelet Guidelines. Antiplatelet Guidelines. PERIOPERATIVE MANAGEMENT OF ANTIPLATELET THERAPY. Working Group: . James D. Douketis MD, FRCP(C); A. Graham . Turpie. MD, FRCP(C). Objectives. Interpret the Canadian Cardiovascular Society . Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Antiplatelet Guidelines. USE OF ANTIPLATELET THERAPY IN WOMEN WHO ARE PREGNANT OR BREASTFEEDING. Working Group: . Wee . Shian. Chan MD, FRCP(C); James D. Douketis MD, FRCP(C). Working Group: . Maria E. Wolfs, MD, FRCP; . Rémi. . Rabasa-Lhoret. , MD, PhD. Canadian Cardiovascular Society Antiplatelet . Guidelines. Objectives. Interpret . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . GRACE. . 5-Year Mortality . Antiplatelet Therapy. Cornerstone of Medical Therapy Post ACS. TRA 2P-TIMI 50. Efficacy/Safety. ATLAS ACS 2—TIMI 51. Study Design. ATLAS-2. . Baseline Patient Characteristics. Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Dilemma: Recent Trials And Guidelines For. Clinical Practice. Dean J. Kereiakes, MD FACC FSCAI. Medical Director, The Christ Hospital Heart & Vascular Center and the Lindner Research Center at The Christ Hospital, Cincinnati, Ohio. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.